Aciphex and Fluvoxamine Interaction
There is no direct evidence of a clinically significant interaction between Aciphex (rabeprazole) and fluvoxamine, and this combination can generally be used together with monitoring. However, fluvoxamine is a potent CYP1A2 and CYP2C19 inhibitor, while rabeprazole is primarily metabolized through non-enzymatic pathways, making it less susceptible to drug interactions than other proton pump inhibitors.
Pharmacokinetic Considerations
Rabeprazole has a unique metabolic advantage - it undergoes predominantly non-enzymatic metabolism rather than relying heavily on CYP enzymes 12. This distinguishes it from other PPIs like omeprazole, which are heavily dependent on CYP2C19 for metabolism. Since rabeprazole is less influenced by CYP2C19 genetic polymorphisms and enzymatic inhibition 1, the theoretical interaction with fluvoxamine (a CYP2C19 inhibitor) is minimal.
Key Safety Points
What Makes This Combination Relatively Safe:
- Rabeprazole's non-enzymatic metabolism pathway reduces susceptibility to CYP-mediated drug interactions 12
- No specific warnings about fluvoxamine interactions appear in the Aciphex FDA label 33
- Rabeprazole has demonstrated a low potential for drug interactions in clinical practice 4
Important Caveats to Monitor:
Watch for general PPI-related adverse effects that may be more pronounced if any interaction occurs:
- Headache, diarrhea, nausea (common rabeprazole side effects) 3
- Hypomagnesemia with prolonged use 33
- Increased risk of C. difficile infection 3
- Bone fracture risk with long-term use 3
Fluvoxamine-specific concerns (unrelated to rabeprazole but important for overall management):
- Fluvoxamine inhibits CYP1A2, CYP2C9, CYP2C19, and P-glycoprotein 5
- Monitor for interactions with other concomitant medications more carefully 5
Clinical Recommendation
Proceed with the combination but:
- Start with standard dosing for both medications
- Monitor for increased rabeprazole effects (though unlikely given its metabolism)
- Be vigilant about fluvoxamine's interactions with OTHER medications the patient may be taking
- Use the shortest duration of PPI therapy appropriate for the condition 3
Contrast with Other PPIs
If you were considering omeprazole instead, there would be a documented significant interaction with fluvoxamine. A study showed fluoxetine (another SSRI with CYP2C19 inhibition) increased omeprazole AUC by 3.5-fold and Cmax by 2.4-fold 6. Rabeprazole's non-enzymatic metabolism makes it the preferred PPI choice when combined with potent CYP2C19 inhibitors like fluvoxamine.